FindTrial
Sign In

The Value of Artificial Intelligence-based 18F-FDG PET/CT in Diferential Diagnosis, Efficacy Prediction and Prognosis Prediction of T-NK Lell Lymphoma: A Clinical Study

The Value of Artificial Intelligence-based 18F-FDG PET/CT in Diferential Diagnosis, Efficacy Prediction and Prognosis Prediction of T-NK Lell Lymphoma: A Clinical Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400090798
Enrollment
Unknown
Registered
2024-10-14
Start date
2024-10-15
Completion date
Unknown
Last updated
2024-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

T-NK cell lymphoma

Interventions

Modeling group:None
Validation group:None

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Pathological histology confirmed as T-NK Cell Lymphoma; 2.18F-FDG PET/CT examination before treatment; 3. Using modern best practice treatment options; 4. Complete clinicopathological and follow-up data were obtained.

Exclusion criteria

Exclusion criteria: 1. The patient had previously received antitumor therapy; 2. The patient had a history of other tumors; 3. Incomplete clinical information or imaging data; 4. Concomitant other malignant tumors.

Design outcomes

Primary

MeasureTime frame
receiver operating characteristic curve, ROC;Progression-Free Survival;Overall Survival;—

Countries

China

Contacts

Public ContactRong Tian

Department of Nuclear Medicine, West China Hospital of Sichuan University

rongtiannuclear@126.com+86 189 8060 1586

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026